Merola, J.; Sofen, H.; Thaci, D.; Paul, C.; Imafuku, S.; Banerjee, . S.; Armstrong , A. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin 2021, 5, s36.